Brokerages forecast that ENDRA Life Sciences Inc (NASDAQ:NDRA) will announce ($0.21) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for ENDRA Life Sciences’ earnings. ENDRA Life Sciences posted earnings per share of ($0.31) in the same quarter last year, which would suggest a positive year over year growth rate of 32.3%. The company is scheduled to issue its next earnings report on Thursday, August 13th.
According to Zacks, analysts expect that ENDRA Life Sciences will report full year earnings of ($0.82) per share for the current financial year. For the next fiscal year, analysts forecast that the business will post earnings of ($0.58) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover ENDRA Life Sciences.
ENDRA Life Sciences (NASDAQ:NDRA) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.29).
Shares of NDRA stock traded down $0.03 during trading hours on Friday, hitting $0.93. 901,000 shares of the company were exchanged, compared to its average volume of 230,386. The firm has a fifty day simple moving average of $0.86 and a 200 day simple moving average of $1.10. The company has a current ratio of 2.43, a quick ratio of 2.32 and a debt-to-equity ratio of 0.13. ENDRA Life Sciences has a 52-week low of $0.60 and a 52-week high of $2.25. The stock has a market capitalization of $13.93 million, a price-to-earnings ratio of -0.41 and a beta of 1.80.
A hedge fund recently raised its stake in ENDRA Life Sciences stock. ICM Asset Management Inc. WA increased its holdings in ENDRA Life Sciences Inc (NASDAQ:NDRA) by 32.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 876,639 shares of the company’s stock after buying an additional 212,755 shares during the period. ENDRA Life Sciences accounts for 0.6% of ICM Asset Management Inc. WA’s investment portfolio, making the stock its 21st biggest position. ICM Asset Management Inc. WA owned approximately 6.37% of ENDRA Life Sciences worth $633,000 as of its most recent SEC filing. 7.86% of the stock is owned by institutional investors and hedge funds.
About ENDRA Life Sciences
ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
See Also: Why do companies engage in swaps?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.